{"groups":[{"description":"0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles","id":"FG000","title":"IPH2101 0.2 mg/kg"},{"description":"2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles","id":"FG001","title":"IPH2101 2 mg/kg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All patients enrolled were screened in order to verify the inclusion/exclusion criteria. All patients enrolled (30 patients) were analyzed.","recruitmentDetails":"There were 44 patients screened, 14 subjects were not randomized, 12 of whom were screen failures, 30 patients randomized."}